MedWatch

Analyst: Ambu's unsightly downgrade is tied to unmet growth expectations

The medtech firm’s Achilles’ heel is its Visualizations business, which might be scaling down in the future, assesses an analyst.

Photo: Ambu / PR

Shareholders of Ambu must be a patient bunch. Again and again, the Danish medtech firm has downgraded its financial expectations – seven times under the previous leadership of the company, and on Wednesday, new Chief Executive Officer Britt Meelby Jensen announced the eighth financial revision.

It doesn’t paint a pretty picture, says Sydbank analyst Søren Løntoft Hansen, but it probably reflects how the company has been biting off more than it can chew.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs